Prediction of the Answer to the Treatment by Biotherapies for Naive Spondyloarthritis by Combinatorial Analysis of Serum Biomarkers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-07-31

Study Completion Date

2018-03-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this trial is the caracterisation of a predicting algorithm of the answering response for patients with etanercept treatment in spondyloarthritis disease.

This algorithm will help to target patients patients who have a risk / benefit important for etanercept treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Defining Remission With Etanercept in AS in Real Life Clinical Practice

NCT02202850

Ankylosing Spondylitis

COMPLETED

Study Evaluating Etanercept in Patients With Ankylosing Spondylitis

NCT00458185

Ankylosing Spondylitis

COMPLETED PHASE4

Study Evaluating Etanercept in Subjects With Ankylosing Spondylitis in Spain

NCT00873730

Ankylosing Spondylitis

COMPLETED PHASE4

Study Evaluating The Use Of Etanercept In Patients With Ankylosing Spondylitis

NCT00544557

Ankylosing Spondylitis

COMPLETED

Observational Non-Interventional Study With Enbrel (Etanercept) in Patients With Ankylosing Spondylitis

NCT01188655

Spondylitis, Ankylosing

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Spondyloarthritis (or spondyloarthropathy) is an inflammatory rheumatic disease that causes arthritis. It differs from other types of arthritis because it involves the sites where ligaments and tendons are attached to bones called "entheses."

All patients should get physical therapy and make exercises for joints. Exercises that promote spinal extension and mobility are the most recommended.

Non-steroidal anti-inflammatory drugs (NSAIDs) are the first line treatment for spondylarthritis. NSAIDs are effective when they are used continuously or at the request, in a short or long-term use. However, physicians have to be aware of potential cardiovascular, renal or gastro-intestinal secondary effects when they prescribe NSAIDs. After NSAIDs failure, TNF inhibitors can be used, like infliximab or etanercept. Before starting an anti-TNF treatment, a screening is mandatory. Indeed, patients treated with an anti-TNF must be followed regularly. Until now, there is no algorithm which can predict the response to TNF-inhibitors, and more especially for etanercept treatment.

In this clinical trial, the investigators want to caracterise an algorithm which can predict the response to etanercept for a cohort of patients who suffer from spondyloarthritis.

The development of a predictive algorithm for etanercept treatment will be set up from biological data and finalized with the availibility of clinical data (M6) of the patients .

A modelling by logistic regression will be used, incorporing the set of available variables.

In this clinical trial, the investigators want to caracterise an algorithm which can predict the response to TNF-inhibitors for a cohort of patients with Spondyloarthritis and for an indicated treatment of etanercept.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Spondylitis, Ankylosing

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

etanercept

The etanercept is not the experimental study drug. Etanercept is a treatment justifying the inclusion of patients and is used in accordance with its marketing authorization.

Modality of administration :

Etanercept : 50 mg / week subcutaneously, every 7 days The clinical response will be evaluated after 6 months of etanercept treatment, at the M6 visit.

Group Type EXPERIMENTAL

Etanercept ® 50 mg

Intervention Type DRUG

The etanercept is not the experimental study drug. Etanercept is a treatment justifying the inclusion of patients and is used in accordance with its marketing authorization.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Etanercept ® 50 mg

The etanercept is not the experimental study drug. Etanercept is a treatment justifying the inclusion of patients and is used in accordance with its marketing authorization.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ENBREL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients with spondylarthritis validating ASAS or New York modified critera, and for who etanercept is indicated.
* Naïve from biological Drug Modifying Anti Rheumatic Drugs
* patients between 18 and 70 years old
* patients who can be monitored at 6 months ;
* patients who can observe the entire treatment ;
* patiens with age to procreate under effective contraception ((abstinence, oral contraceptives , intrauterine devices , implants, spermicide or surgical sterilization ) during the study and for 6 months, 3 weeks after the last injection.
* patients able to understand and accept the terms of the study
* patients having signed the informed consent.
* patients insured under social security

Exclusion Criteria

* patients of age protected ;
* patients with difficulties for understanding french language ;
* patients with high function disorders incompatible with an education program (dementia Alzheimer's type , etc ...) ;
* patients with psycho- social instability incompatible with regular monitoring (homeless , addictive behavior ,etc.) ;
* patients in a socio- professional situation incompatible with optimal attendance to the program - - Pregnant or nursing patients
* contraindication to the use of anti- TNF treatment
* Surgery scheduled during the study.
* Persons mentioned in Articles L.1121-5 to L.1121-8 of the Public Health Code

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No